Positive News SentimentPositive NewsNASDAQ:TCRX TScan Therapeutics (TCRX) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free TCRX Stock Alerts $7.94 -0.36 (-4.34%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$7.28▼$8.2950-Day Range$4.89▼$8.3052-Week Range$1.62▼$9.00Volume741,662 shsAverage Volume174,898 shsMarket Capitalization$380.17 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get TScan Therapeutics alerts: Email Address TScan Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside57.4% Upside$12.50 Price TargetShort InterestHealthy0.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.61Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.18) to ($1.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.41 out of 5 starsMedical Sector549th out of 939 stocksBiological Products, Except Diagnostic Industry93rd out of 158 stocks 3.5 Analyst's Opinion Consensus RatingTScan Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, TScan Therapeutics has a forecasted upside of 57.4% from its current price of $7.94.Amount of Analyst CoverageTScan Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.52% of the float of TScan Therapeutics has been sold short.Short Interest Ratio / Days to CoverTScan Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TScan Therapeutics has recently increased by 0.32%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTScan Therapeutics does not currently pay a dividend.Dividend GrowthTScan Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCRX. Previous Next 2.6 News and Social Media Coverage News SentimentTScan Therapeutics has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for TScan Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for TCRX on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added TScan Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TScan Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.27% of the stock of TScan Therapeutics is held by insiders.Percentage Held by Institutions82.83% of the stock of TScan Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TScan Therapeutics are expected to grow in the coming year, from ($1.18) to ($1.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TScan Therapeutics is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TScan Therapeutics is -4.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTScan Therapeutics has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About TScan Therapeutics Stock (NASDAQ:TCRX)TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More TCRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCRX Stock News HeadlinesMarch 26, 2024 | finance.yahoo.comHedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%March 17, 2024 | investorplace.comLow-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck WithMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 11, 2024 | markets.businessinsider.comPositive Outlook for TScan Therapeutics with Promising Clinical Trials and Strong Financial PositionMarch 7, 2024 | markets.businessinsider.comStrong Buy Rating for TScan Therapeutics Amidst Promising Drug Developments and Financial HealthMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for TScan Therapeutics Following Promising Phase 1 ResultsMarch 7, 2024 | finance.yahoo.comTScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical PipelineMarch 6, 2024 | benzinga.comTScan Therapeutics: Q4 Earnings InsightsMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…March 6, 2024 | investorplace.comTCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023March 6, 2024 | globenewswire.comTScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 28, 2024 | globenewswire.comTScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | markets.businessinsider.comStrong Buy Rating for TScan Therapeutics Backed by Positive Phase 1 Trial Data and Promising Treatment EfficacyFebruary 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for TScan Therapeutics Following Promising TCR-T Therapy Trial OutcomesFebruary 26, 2024 | globenewswire.comTScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTRFebruary 21, 2024 | markets.businessinsider.comBuy Rating for TScan Therapeutics Supported by Iovance’s FDA Approval and Promising TIL Therapy BenchmarkFebruary 19, 2024 | finance.yahoo.comTScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?February 14, 2024 | baystreet.caGlobal Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer RatesFebruary 14, 2024 | finance.yahoo.comTScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTRFebruary 14, 2024 | globenewswire.comTScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTRFebruary 6, 2024 | finance.yahoo.comTScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical DevelopmentJanuary 30, 2024 | msn.comTScan Therapeutics Welcomes Jason Amello as New CFOJanuary 29, 2024 | markets.businessinsider.comTScan Appoints Jason Amello As CFOJanuary 29, 2024 | msn.comTScan Therapeutics appoints CFOJanuary 29, 2024 | finance.yahoo.comTScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial OfficerJanuary 18, 2024 | finance.yahoo.comTScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTRJanuary 5, 2024 | markets.businessinsider.comStrong Buy Rating for TScan Therapeutics Amid Progressive Clinical AdvancementsSee More Headlines Receive TCRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/06/2024Today3/28/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCRX CUSIPN/A CIK1783328 Webwww.tscan.com Phone857-399-9500FaxN/AEmployees154Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$15.00 Low Stock Price Target$10.00 Potential Upside/Downside+57.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,220,000.00 Net Margins-423.86% Pretax Margin-423.86% Return on Equity-60.65% Return on Assets-33.86% Debt Debt-to-Equity Ratio0.18 Current Ratio6.51 Quick Ratio6.51 Sales & Book Value Annual Sales$21.05 million Price / Sales18.06 Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book2.52Miscellaneous Outstanding Shares47,880,000Free Float43,922,000Market Cap$380.17 million OptionableNot Optionable Beta0.87 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Gavin MacBeath Ph.D. (Age 54)CEO & Director Comp: $650.17kDr. Stephen J. Elledge Ph.D.Co-Founder & Chairman of Scientific Advisory BoardMr. Tomasz Kula Ph.D.Co-Founder & Member of Advisory BoardMr. Jason A. Amello (Age 56)Chief Financial Officer Mr. Leiden Dworak M.B.A.Principal Accounting Officer & TreasurerDr. Justin McCue Ph.D.Chief Technology OfficerDr. Zoran Zdraveski J.D. (Age 53)Ph.D., Chief Legal & Strategy Officer and Company Secretary Ms. Ann HargravesSenior Vice President of Human ResourcesDr. Shrikanta Chattopadhyay M.D.Senior VP & Head of Translational MedicineDr. Debora Barton M.D. (Age 48)Chief Medical Officer More ExecutivesKey CompetitorsTenaya TherapeuticsNASDAQ:TNYAProKidneyNASDAQ:PROKLexeo TherapeuticsNASDAQ:LXEOKodiak SciencesNASDAQ:KODMeiraGTxNASDAQ:MGTXView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 35,558 shares on 3/11/2024Ownership: 3.739%Goldman Sachs Group Inc.Bought 30,285 shares on 3/1/2024Ownership: 0.063%Virtu Financial LLCBought 18,418 shares on 2/26/2024Ownership: 0.039%Vanguard Group Inc.Bought 35,558 shares on 2/15/2024Ownership: 3.739%Pale Fire Capital SEBought 4,998 shares on 2/14/2024Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions TCRX Stock Analysis - Frequently Asked Questions Should I buy or sell TScan Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCRX shares. View TCRX analyst ratings or view top-rated stocks. What is TScan Therapeutics' stock price target for 2024? 3 analysts have issued 1 year price targets for TScan Therapeutics' shares. Their TCRX share price targets range from $10.00 to $15.00. On average, they predict the company's share price to reach $12.50 in the next twelve months. This suggests a possible upside of 57.4% from the stock's current price. View analysts price targets for TCRX or view top-rated stocks among Wall Street analysts. How have TCRX shares performed in 2024? TScan Therapeutics' stock was trading at $5.83 at the beginning of the year. Since then, TCRX stock has increased by 36.2% and is now trading at $7.94. View the best growth stocks for 2024 here. When is TScan Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our TCRX earnings forecast. How were TScan Therapeutics' earnings last quarter? TScan Therapeutics, Inc. (NASDAQ:TCRX) released its quarterly earnings results on Wednesday, March, 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.08. The firm earned $7.21 million during the quarter, compared to analysts' expectations of $2.94 million. TScan Therapeutics had a negative trailing twelve-month return on equity of 60.65% and a negative net margin of 423.86%. What ETF holds TScan Therapeutics' stock? Simplify Propel Opportunities ETF holds 1,046,916 shares of TCRX stock, representing 2.20% of its portfolio. When did TScan Therapeutics IPO? TScan Therapeutics (TCRX) raised $100 million in an IPO on Friday, July 16th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share. Who are TScan Therapeutics' major shareholders? TScan Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.74%), Vanguard Group Inc. (3.74%), abrdn plc (0.42%), Stifel Financial Corp (0.25%), Balyasny Asset Management L.P. (0.10%) and Goldman Sachs Group Inc. (0.06%). Insiders that own company stock include Barbara Klencke, Brian M Silver, David P Southwell, Gavin Macbeath, Lynx1 Capital Management Lp, Timothy J Barberich and Zoran Zdraveski. View institutional ownership trends. How do I buy shares of TScan Therapeutics? Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.